Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Valanbio Therapeutics Inc
Profile last edited on: 6/21/21      CAGE: 7GYE0      UEI: KKFTU8J72323

Business Identifier: Novel antibiotics
Year Founded
2015
First Award
2020
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

4101 Lake Boone Trail Suite 300
Raleigh, NC 27607
   N/A
   valanbioinfo@gmail.com
   N/A
Location: Single
Congr. District: 02
County: Wake

Public Profile

An early-stage anti-infectives company, Valanbio Therapeutics Inc develops novel antibiotics for Gram-negative organisms. Among other projects, the company is studying the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$797,403
Phase II Dollars
$794,342
Total Awarded
$1,591,745

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 2 NIH $1,591,745
Project Title: Ind-Enabling Studies of the Potent Lpxc Inhibitor Lpc-233 as a Novel Antibiotic Against Gram-Negative Pathogens

Key People / Management

  Clayton Duncan -- CEO

  S hopkins

Company News

There are no news available.